Search
for
Sort by
Research 151–180 of 1000+
- Biologics in the management of childhood atopic dermatitis
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
- Hairy tongue associated with the use of baricitinib therapy for ophiasis pattern alopecia areata
- Hair today, gone tomorrow
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
- Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Common Causes of Hair Loss
- Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
- Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
- Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Evolving treatment paradigms in dermatology: Insights from emerging and repurposed therapies
- Deuruxolitinib for Alopecia Areata.
- Hypohidrotic Ectodermal Dysplasia with c.28delG Mutation in Ectodysplasin A Gene and Severe Atopic Dermatitis Treated Successfully with Tofacitinib
- Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment
- Review of modern methods of treating vitiligo
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Tofacitinib in the Management of Alopecia Universalis
- Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Ann Robinson’s research reviews —12 May 2022
- America - A Diversity of Life Styles.
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Janus kinase inhibitors for alopecia areata: a review of clinical data